| Literature DB >> 34006245 |
Nwora Lance Okeke1, Tony McLaurin2, Ruth Gilliam-Phillips3, David H Wagner4, Valerie J Barnwell3, Yolanda M Johnson4, Osaffo James3, Padonda B Webb4, Sharon D Parker5, Bendu Hill2, Mehri S McKellar6, John T Mitchell2.
Abstract
BACKGROUND: Despite young African American adults (ages 18-24) being among the highest risk groups for HIV infection, little is known about their awareness of HIV pre-exposure prophylaxis (PrEP) - a once daily pill shown to be > 90% effective in preventing HIV. To explore awareness and acceptability of PrEP among college students in this demographic, we conducted a survey of attendees at two large historically Black universities (HBCU) in North Carolina.Entities:
Keywords: HIV; Historically black colleges and universities; PrEP; Pre-exposure prophylaxis; Sexual health
Mesh:
Year: 2021 PMID: 34006245 PMCID: PMC8132367 DOI: 10.1186/s12889-021-10996-2
Source DB: PubMed Journal: BMC Public Health ISSN: 1471-2458 Impact factor: 3.295
Demographics of Survey Respondents (n = 210)
| Characteristic | All ( |
|---|---|
| | 53 (25) |
| | 158 (75) |
| | 0 |
| 19.8 (1.8) | |
| | 186 (89) |
| | 5 (2) |
| | 9 (4) |
| | 6 (3) |
| | 4 (2) |
| | 81 (39) |
| | 47 (22) |
| | 51 (24) |
| | 23 (11) |
| | 5 (2) |
| | 3 (1) |
Student responses to survey on PrEP awareness
| Characteristic | N (%) |
|---|---|
| | 110 (52) |
| | 100 (48) |
| | 2 (3) |
| | 58 (97) |
| | 4 (7) |
| | 9 (17) |
| | 2 (4) |
| | 8 (15) |
| | 4 (7) |
| | 13 (24) |
| | 2 (4) |
| | 10 (19) |
| | 2 (4) |
| | 21 (39) |
| | 12 (22) |
| | 11 (20) |
| | 7 (13) |
| | 3 (6) |
| | 153 (73) |
| | 33 (16) |
| | 14 (7) |
| | 4 (2) |
| | 6 (3) |
| | 122 (58) |
| | 39 (19) |
| | 49 (23) |
| | 107 (51) |
| | 57 (27) |
| | 46 (22) |
| | 120 (57) |
| | 47 (22) |
| | 43 (20) |
| | 62 (29) |
| | 30 (14) |
| | 79 (38) |
| | 39 (19) |
| | 145 (69) |
| | 65 (31) |
aSample size varies for each item due to equipment malfunction
Relative risk of PrEP awareness associated with selected demographic characteristics
| Characteristic | Relative Risk (95% CI) | ||
|---|---|---|---|
| Bivariable | Multivariable | ||
| 0.87 (0.55–1.36) | 0.81 (0.41–1.57) | 0.53 | |
| 0.95 (0.85–1.07) | 0.93 (0.75–1.16) | 0.54 | |
| 1.14 (0.78–1.67) | 1.01 (0.20–4.98) | 0.99 | |
| 1.04 (0.54–1.99) | 0.94 (0.20–4.47) | 0.94 | |
| 0.68 (0.36–1.28) | 0.85 (0.19–3.83) | 0.84 | |
| 0.99 (0.55–1.81) | 1.04 (0.21–5.31) | 0.96 | |
| 1.05 (0.56–1.97) | 1.10 (0.42–2.84) | 0.84 | |
| 1.05 (0.69–1.60) | 1.11 (0.60–2.09) | 0.74 | |
Adjusted relative risks for factors associated with acceptability of PreP by mode and frequency of administration
| Characteristic | Daily PrEP | Monthly Injection = (RR 95% CI) | Every 2 month injection (RR 95% CI) | Any Prep RR (95% CI) | ||||
|---|---|---|---|---|---|---|---|---|
| 0.74 (0.37–1.48) | 0.40 | 0.67 (0.34–1.33) | 0.25 | 0.62 (0.31–1.21) | 0.16 | 0.78 (0.38–1.60) | 0.51 | |
| 0.98 (0.79–1.23) | 0.90 | 1.14 (0.91–1.42) | 0.25 | 1.10 (0.88–1.37) | 0.40 | 1.05 (0.83–1.33) | 0.70 | |
| 1.24 (0.60–2.57) | 0.55 | 1.72 (0.84–3.51) | 0.13 | 1.80 (0.89–3.69) | 0.10 | 1.33 (0.62–2.86) | 0.45 | |
| 1.03 (0.51–2.05) | 0.92 | 0.68 (0.35–1.35) | 0.27 | 0.82 (0.41–1.60) | 0.56 | 0.92 (0.45–1.88) | 0.82 | |
| 0.83 (0.40–1.73) | 0.63 | 0.76 (0.37–1.55) | 0.45 | 0.79 (0.38–1.60) | 0.51 | 0.69 (0.32–1.49) | 0.35 | |
| 1.60 (0.59–4.38) | 0.35 | 1.74 (0.65–4.66) | 0.26 | 1.43 (0.53–3.83) | 0.48 | 2.32 (0.70–7.67) | 0.17 | |
| 2.27 (0.76–6.81) | 0.14 | 1.28 (0.48–3.37) | 0.62 | 1.22 (0.45–3.29) | 0.69 | 2.51 (0.69–9.11) | 0.16 | |
| 1.23 (0.64–2.38) | 0.52 | 1.60 (0.77–3.32) | 0.21 |